ResearcherHarvard UniversityActive in the last 2 years
Peter D. Caravan
Matched on ORCID iD 0000-0002-3179-6537; OpenAlex author ID A5022556494. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 4)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 28
2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 2 papers · 2025: 1 paper
Papers 6
- Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment. Last author DOI 10.1158/0008-5472.can-24-3384↗
- Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-23-3548↗
- Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-human translational studies. Last author DOI 10.7150/thno.100116↗
- Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI. Co-author DOI 10.1158/1078-0432.ccr-18-1359↗
- Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. Co-author DOI 10.1242/dmm.034793↗
- Molecular MR imaging of fibrosis in a mouse model of pancreatic cancer. Last author DOI 10.1038/s41598-017-08838-6↗
Closest collaborators
The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kenneth K. Tanabe · 5 shared papers, 2018–2025 · strength 0.70
- Paper Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer. DOI 10.1158/0008-5472.can-23-3548↗
- Paper Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibito… DOI 10.1158/0008-5472.can-24-3384↗
- Paper Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-huma… DOI 10.7150/thno.100116↗
- Motaz Qadan · 3 shared papers, 2020–2025 · strength 0.42
- Paper Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibito… DOI 10.1158/0008-5472.can-24-3384↗
- Paper Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-huma… DOI 10.7150/thno.100116↗
- Paper Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targete… DOI 10.1158/1078-0432.ccr-18-1359↗
- Shadi Abdar Esfahani · 2 shared papers, 2024 · strength 0.35
- Hua Ma · 2 shared papers, 2024 · strength 0.35
- Nabeel M. Bardeesy · 3 shared papers, 2018–2025 · strength 0.35
- Paper Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibito… DOI 10.1158/0008-5472.can-24-3384↗
- Paper Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targete… DOI 10.1158/1078-0432.ccr-18-1359↗
- Paper Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. DOI 10.1242/dmm.034793↗
- Michael D. Lanuti · 3 shared papers, 2018–2024 · strength 0.30
- Paper Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-huma… DOI 10.7150/thno.100116↗
- Paper Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targete… DOI 10.1158/1078-0432.ccr-18-1359↗
- Paper Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. DOI 10.1242/dmm.034793↗
- Veronica Clavijo Jordan · 2 shared papers, 2020–2025 · strength 0.27
- Paper Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibito… DOI 10.1158/0008-5472.can-24-3384↗
- Paper Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targete… DOI 10.1158/1078-0432.ccr-18-1359↗
- Andrew Scott Liss · 1 shared paper, 2024 · strength 0.20
- Ibrahim Ragab Eissa · 1 shared paper, 2025 · strength 0.19
- Stuti G. Shroff · 1 shared paper, 2025 · strength 0.19
- Derek J. Erstad · 2 shared papers, 2018–2020 · strength 0.15
- Paper Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targete… DOI 10.1158/1078-0432.ccr-18-1359↗
- Paper Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. DOI 10.1242/dmm.034793↗
- Cristina R. Ferrone · 2 shared papers, 2018–2020 · strength 0.15
- Paper Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targete… DOI 10.1158/1078-0432.ccr-18-1359↗
- Paper Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. DOI 10.1242/dmm.034793↗
- Bryan C. Fuchs · 2 shared papers, 2018–2020 · strength 0.15
- Paper Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targete… DOI 10.1158/1078-0432.ccr-18-1359↗
- Paper Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. DOI 10.1242/dmm.034793↗
- David Tsai Ting · 1 shared paper, 2024 · strength 0.15
- Theodore Sunki Hong · 1 shared paper, 2024 · strength 0.15
- Carlos Fernández-del Castillo · 1 shared paper, 2024 · strength 0.15
- Onofrio A. Catalano · 1 shared paper, 2024 · strength 0.15
- Genevieve Marie Boland · 1 shared paper, 2024 · strength 0.15
- Hannah Johnson Roberts · 1 shared paper, 2024 · strength 0.15
- Aparna R. Parikh · 1 shared paper, 2024 · strength 0.15
- Colin D. Weekes · 1 shared paper, 2024 · strength 0.15
- Christian T. Farrar · 1 shared paper, 2020 · strength 0.08
- Theodoros P. Michelakos · 1 shared paper, 2020 · strength 0.08
- Vikram Deshpande · 1 shared paper, 2020 · strength 0.08
- Valerie Humblet · 1 shared paper, 2020 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.